Anti-Venom Market

Market Overview:

The global anti-venom market size reached US$ 1,096.1 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,644.9 Million by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2023-2028. The rising incidences of snake bites and scorpion stings, the implementation of favorable government initiatives, and ongoing innovations in the industry represent some of the key factors driving the market.

Anti-venom, also known as venom antiserum, refers to a type of medication used to treat the effects of venomous bites or stings from animals, including snakes, spiders, scorpions, and certain marine creatures such as jellyfish or cone snails. It is obtained by extracting venom from the offending animal and then injecting small amounts of the venom into animals, such as horses, sheep, or goats, whose immune systems produce antibodies that are harvested and purified to create anti-venom. Anti-venom neutralizes the toxins and counteracts the effects of the venom, preventing them from causing life-threatening complications such as respiratory failure or organ damage. It is extensively adopted across the globe in treating venomous bites and stings, depending on their history, examination, and geographic, clinical, and pathologic factors.

Anti-Venom Market Trends:

The rise in cases of venomous bites and stings across the world, particularly in rural and tropical regions and among agricultural workers and hunters, represents one of the prime factors driving the market growth. Besides this, the escalating consumer awareness of the importance of snake bite prevention and easy product availability at an affordable price is creating a favorable outlook for the market. Moreover, the implementation of numerous government initiatives to combat snake bites, such as education and training programs, and intensive investments in research and development (R&D) activities of new anti-venom products are contributing to the market growth. In addition to this, with the rising demand for animal-based protein, there is an increase in the number of livestock and other animals at risk of snake bites, which, in turn, is presenting remunerative growth opportunities for the market. Concurrent with this, the rising popularity of traveling and exploring exotic destinations, such as islands, deserts, jungles, and safaris, that puts tourists at risk of snake bites and other venomous animal encounters is acting as another significant growth-inducing factor. Furthermore, numerous technological advancements in the biotechnology and healthcare industries and ongoing innovative improvements in manufacturing technology, allowing for the production of more effective and efficient anti-venom products, are positively impacting the market growth. Apart from this, the launch of various rapid snake venom detection kits, which utilize a rapid enzyme immunoassay to detect and identify snake venom through samples taken from bite sites, urine, plasma, blood, or other tissues and body fluids, is propelling the market forward.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-venom market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on species, anti-venom type, mode of action and end user.

Species Insights:

• Snake
• Scorpion
• Spider
• Others
   

The report has provided a detailed breakup and analysis of the anti-venom market based on the species. This includes snake, scorpion, spider, and others. According to the report, snake represented the largest segment.

Anti-venom Type Insights:

• Polyvalent Anti-venom
• Monovalent Anti-venom
   

A detailed breakup and analysis of the anti-venom market based on the anti-venom type has also been provided in the report. This includes polyvalent and monovalent anti-venom. According to the report, polyvalent anti-venom accounted for the largest market share.

Mode of Action Insights:

• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others
   

The report has provided a detailed breakup and analysis of the anti-venom market based on the mode of action. This includes cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others. According to the report, neurotoxic represented the largest segment.

End User Insights:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
   

A detailed breakup and analysis of the anti-venom market based on the end user has also been provided in the report. This includes hospitals, clinics, and ambulatory surgical centers. According to the report, hospitals accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-venom. Some of the factors driving the North America anti-venom market included the increasing incidence of snake bites, the introduction of numerous favorable government initiatives, and the thriving travel and tourism sector.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-venom market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc., and Rare Disease Therapeutics Inc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the anti-venom market from 2017-2028.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global anti-venom market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the anti-venom industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.